By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
October 30, 2025 11:09 PM EDT
Medical Herald
Search
  • Health Conditions
    Health ConditionsShow More
    Beware of Counterfeit Weight Loss Drugs Sold Online
    Weight Management
    Father’s Back Pain Leads to Tragic Cancer Diagnosis
    Cancer
    Novo Nordisk’s CEO Emphasizes Strategic Risks to Lead Obesity Market
    Weight Management
    Medtronic Launches Ankle Implant for Bladder Control
    Health Conditions
    Stewart’s Caring Place Highlights All Cancer Awareness in October
    Breast Cancer
  • Wellness & Self-Care
    Wellness & Self-CareShow More
    Pureance HydraLift: A Scientific Approach to Hair Care
    Wellness & Self-Care
    Jewel Reflects on Fame and Mental Health Advocacy Journey
    Mental Health
    Discover the Health Benefits of Hazelnuts
    Healthy Living
    How the Government Shutdown Affects Health Insurance Costs
    Wellness & Self-Care
    NYC Sues Tech Giants Over Youth Mental Health Crisis
    Mental Health
  • Nutrition & Fitness
    Nutrition & FitnessShow More
    Delicious Roasted Salmon with Olives from Dan Pelosi
    Healthy Recipes
    Short Exercise Bursts: A New Trend in Fitness?
    Fitness
    PepsiCo Launches Protein-Focused Beverages to Meet Demand
    Diet & Nutrition
    Calcium Loaf: A Depression-Era Recipe for Today’s Food Challenges
    Healthy Recipes
    Effective Full-Body Workout Enhances Testosterone and Muscle
    Fitness
  • Innovation
    InnovationShow More
    Understanding Superspreading and Pathogen Virulence Evolution
    Innovation
    Starkey Launches Innovative AI Hearing Aid for All Generations
    Innovation
    AstraZeneca Boosts Virginia Investment to $4.5 Billion for Drug Production
    Drugs & Medications
    How ALV-J Virus Bypasses Immune Defense Using miR-155
    Innovation
    Nursing Homes’ Use of Painkillers and Antidepressants Raises Risks
    Drugs & Medications
  • News
    NewsShow More
    Diet Coke Lime Set to Return in 2025 After Seven-Year Hiatus
    News
    Dublin Environmentalists Celebrate Tentative Repeal of Measure II
    News
    Trust in CDC Plummets Under Kennedy’s Leadership, Poll Reveals
    News
    St. Joseph Plans New Community Center and Cannabis Dispensary
    News
    Harry and Meghan Shine at World Mental Health Day Gala in NYC
    News
Font ResizerAa
Medical HeraldMedical Herald
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Search
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Follow US
Copyright © 2025, Medical Herald. All Rights Reserved.
Home » Innovation » Telomir Pharmaceuticals Sees 39% Surge After Positive Study Results

Telomir Pharmaceuticals Sees 39% Surge After Positive Study Results

By Samuel Lee
Published: October 10, 2025
Share

Telomir Pharmaceuticals Inc. (NASDAQ:TELO) experienced a significant boost in after-hours trading on Monday, with shares climbing 38.71% to reach $1.97. This surge followed the release of promising preclinical study results concerning its leading compound, Telomir-1.

Contents
  • Key Study Findings on DNA Methylation
  • Ongoing Development
  • Stock Performance Overview
  • Conclusion

The day’s trading began with a modest increase, as the stock edged up 1.43% during regular hours, closing at $1.42 based on data from Benzinga Pro.

Key Study Findings on DNA Methylation

In a filing with the SEC under Form 8-K, the Florida-based biotechnology company disclosed findings from research indicating that Telomir-1 demonstrated the ability to reverse abnormal deoxyribonucleic acid (DNA) methylation in aggressive prostate cancer models.

This reversal was significant as it restored the function of two essential tumor suppressor genes—MASPIN and RASSF1A—which are frequently silenced in cancer due to hypermethylation.

1. MASPIN’s Role: According to the company’s report, MASPIN plays several crucial roles in cancer defense mechanisms:

– It blocks tumor invasion and regulates cell migration and angiogenesis.
– It promotes apoptosis (programmed cell death).
– It enhances sensitivity to treatments.

Telomir-1 effectively reversed chemotherapy-induced DNA methylation, restoring MASPIN’s activity in living models (in vivo).

2. RASSF1A Functionality: RASSF1A is critical for:

– Regulating cell cycle control
– Promoting apoptosis
– Suppressing metastasis.

The findings indicated that Telomir-1 reduced RASSF1A methylation in a dose-dependent manner. Enhanced effects were observed particularly when Telomir-1 was administered alongside chemotherapy.

Ongoing Development

Telomir Pharmaceuticals has announced that it will continue its preclinical development alongside studies designed to enable Investigational New Drug (IND) applications, underscoring the ongoing commitment to advancing its pipeline.

Stock Performance Overview

Despite the recent uptick, TELO has struggled throughout the year, currently down 65.53% year-to-date. However, it has shown signs of recovery, posting a 15.45% gain in the past month. Over the last year, shares have fluctuated between $1.12 and $7.08, reflecting the volatility within the market.

The company currently holds a market capitalization of $45.84 million and has an average daily trading volume of 3.33 million shares. An analysis from Benzinga Edge Stock Rankings reveals a concerning negative price trend for TELO across all time frames, indicating potential challenges ahead.

Conclusion

As Telomir Pharmaceuticals continues to develop Telomir-1, the recent study results have sparked renewed interest in the stock. Investors and analysts will be closely watching how the company navigates its next steps in the challenging biotech landscape, particularly in regard to its ongoing preclinical studies. The potential impact on the treatment of aggressive prostate cancer could position Telomir-1 as a significant player in the field if future results align with these promising findings.Drugs & Medications

TAGGED:Telomir Pharmaceuticals
Share This Article
Facebook LinkedIn Email Copy Link
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

HOT NEWS

Diet Coke Lime Set to Return in 2025 After Seven-Year Hiatus

October 30, 2025

Understanding Superspreading and Pathogen Virulence Evolution

Superspreading alters how pathogens evolve, influencing virulence, transmission, and long-term epidemic behavior across diverse host…

October 30, 2025

Dublin Environmentalists Celebrate Tentative Repeal of Measure II

A judge ruled Dublin must conduct an environmental review of Measure II, a controversial plan…

October 30, 2025

Delicious Roasted Salmon with Olives from Dan Pelosi

Dan Pelosi’s roasted salmon with Castelvetrano olives and orange zest blends freshness, simplicity, and flavor…

October 30, 2025

YOU MAY ALSO LIKE

Annual COVID Vaccines Essential for Severe Disease Protection

A new study reveals COVID boosters cut deaths by 64% and hospitalizations by 39%, offering protection across all age groups…

October 21, 2025

Direct Reduced Iron Market Set for Steady Growth Through 2034

The global Direct Reduced Iron market is projected to reach $96.4B by 2034, fueled by sustainable steelmaking and clean energy…

October 10, 2025

Skye Bioscience’s Weight Loss Drug Underwhelms in Phase 2 Trial

Skye Bioscience shares sank 60% as its drug nimacimab missed weight-loss goals, though combo data with semaglutide hinted at potential…

October 8, 2025

AI and Precision Mental Health: Transforming Care with Technology

AI is transforming mental health care through precision treatments, digital twins, and multi-modal diagnostics for more personalized, data-driven therapy.

October 1, 2025

Medical Herald is your trusted source for medical news, scientific research, health policy updates, and expert insights from around the world. 

Category

  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
  • Privacy Policy
  • About Us
  • Contact

Follow US: 

  • Grow Big Agency Sites:
  • London Business Journal
Copyright © 2025, Medical Herald. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?